Energy balance and metabolic changes with SGLT2 inhibition.

Energy balance and metabolic changes with SGLT2 inhibition. Diabetes Obes Metab. 2015 Sep 25; Authors: Rajeev SP, Cuthbertson DJ, Wilding JP Abstract Sodium-glucose co-transporter 2 (SGLT2) inhibitors are the latest addition to the class of oral glucose-lowering drugs. They have been rapidly adopted into clinical practice due to therapeutic advantages including weight loss and reduction in blood pressure in addition to glycaemic benefits and a low intrinsic risk of hypoglycaemia. Although there are extensive data on the clinical effects of SGLT2 inhibition, the metabolic effects of inhibiting renal glucose re-absorption have not been fully described. Recent studies have identified compensatory metabolic effects such as an increase in endogenous glucose production and also shown an increase in glucagon secretion during SGLT2 inhibition. There is also a discrepancy between the expected and observed weight loss from clinical studies on SGLT2 inhibitors, probably due to changes in energy balance with this treatment approach. SGLT2 inhibition is likely to have intriguing effects on whole body metabolism which have not been fully elucidated, and if explained might help optimise the use of this new class of medicines. PMID: 26403227 [PubMed - as supplied by publisher]
Source: Diabetes Metab - Category: Endocrinology Authors: Tags: Diabetes Obes Metab Source Type: research